Yield10 Bioscience Inc Stock Price, News & Analysis

Yield10 Bioscience, Inc. (Nasdaq:YTEN) announced the renaming of its Canadian subsidiary to Yield10 Oilseeds Inc. on July 12, 2022. This branding alignment highlights their focus on innovation in oilseed crops, aiming to enhance global food security and address environmental challenges. Established in 2010 and located in Saskatoon, Yield10 Oilseeds is responsible for developing and field-testing Camelina varieties with traits for biofuels and animal feed. CEO Oliver Peoples emphasized this step to strengthen grower engagement and expand Camelina production.

Yield10 Bioscience, an agricultural bioscience company, announced that its Chief Science Officer, Dr. Kristi Snell, will present at the CROPS 2022 Conference in Huntsville, Alabama, on June 15. Her presentation, titled "Breakthroughs in Plant Based Polyhydroxybutyrate (PHB) Production," focuses on the sustainable production of PHA bioplastics in Camelina seeds. Yield10's research indicates PHA yields of up to 10.2% in Camelina seeds, with ongoing developments aimed at achieving 10-20% yields. This innovation could open new market opportunities for farmers and address global plastic waste issues.

Yield10 Bioscience (Nasdaq: YTEN) announced that its President and CEO, Oliver Peoples, Ph.D., will present a corporate overview at the H.C. Wainwright Global Hybrid Investment Conference, taking place from May 23-26, 2022, at the Fontainebleau Hotel in Miami Beach, FL. The presentation will be available on demand starting at 7:00 am ET on May 24 through May 26. Yield10 focuses on agricultural bioscience, aiming to develop improved Camelina varieties for renewable diesel, bioplastics, and omega-3 oils. More information is available on their website.

Yield10 Bioscience (Nasdaq:YTEN) reported a net loss of $3.3 million for Q1 2022, increased from a net loss of $2.6 million a year prior. Cash and investments decreased to $12.7 million, prompting the company to estimate total net cash usage between $12.0 and $12.5 million for the full year. Key developments include hiring Darren Greenfield as senior director of seed operations and ongoing efforts to commercialize Camelina for biofuel and omega-3 oil markets. The ongoing geopolitical and COVID-19 challenges may impact operations, but the company remains focused on its objectives.

Yield10 Bioscience, Inc. (Nasdaq:YTEN) will report its Q1 2022 financial results on May 11, 2022. Following the earnings announcement, management will host a conference call at 4:30 p.m. ET to discuss financial highlights and provide a business update. Interested parties can access the live call by phone or via a webcast. A replay will be available shortly after the call, lasting until May 25, 2022. Yield10 focuses on developing improved Camelina varieties using its 'Trait Factory' platform for agricultural and food industry applications.

Yield10 Bioscience announced the appointment of Willie Loh, Ph.D., as a special advisor to its Board of Directors and Management, effective immediately. Loh brings extensive experience from Cargill's Global Edible Oils Division, where he focused on market development for oils. His expertise is particularly significant as Yield10 aims to commercialize its Camelina oil platform amidst rising global vegetable oil demand, driven by biofuels and human nutrition. Loh's strategic insights are expected to enhance Yield10's market engagement as they progress towards commercialization.

Yield10 Bioscience, Inc. (Nasdaq:YTEN) announced that President and CEO Oliver Peoples will participate in the Maxim Group 2022 Virtual Growth Conference from March 28-30, 2022. Dr. Peoples is set to present a corporate overview, available at 9:00 am ET on March 28. Additionally, he will engage in a live fireside chat with Anthony Vendetti at 11:30 am ET on the same day. Investors can register for the conference and request one-on-one meetings with management. Yield10 focuses on agricultural bioscience, developing improved Camelina varieties and high-value genetic traits.

Yield10 Bioscience (Nasdaq: YTEN) announced its focus on Camelina as a renewable source of feedstock oil for the biofuels market in the U.S. and Canada. The company’s CEO, Dr. Oliver Peoples, presented at the Advanced Bioeconomy Leadership Conference 2022, emphasizing Camelina's sustainability benefits and its potential for low-carbon biofuels. Yield10 aims to escalate Camelina seed production and collaborate with supply chain partners. The company published a white paper outlining its biofuels and bioplastics development strategy.

Yield10 Bioscience (Nasdaq:YTEN) reported its financial results for 2021, emphasizing its focus on commercializing Camelina for renewable diesel production. The company achieved a net loss of $11.0 million, or $2.33 per share, compared to a loss of $10.2 million in 2020. Cash on hand increased to $16.0 million from $9.7 million year-over-year. Yield10 is advancing its research in PHA bioplastics and omega-3 oils, with plans for a 2022 field test program and ongoing commercialization activities despite potential COVID-19 impacts.